Pharmaceutical manufacturers of Etodolac

Lonza stands as a prominent supplier in the Pharma&Biotech and Specialty Ingredient markets on a global scale. Our utilization of science and technology allows us to develop a diverse range of products that promote healthier lives for both humans and animals, while also improving overall well-being. The selection includes active pharmaceutical ingredients, stem-cell therapies, drinking water sanitizers, industrial preservatives, microbial control solutions, vitamin B compounds, organic personal care ingredients, and agricultural services and products.

Emcure Pharmaceuticals is driven by the purpose to develop, manufacture and market a broad range of pharmaceutical products globally. Our core strength and competitive advantage lie in our established presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV among others. Emcure has launched 6 Biologics in the Domestic Market & RoW markets & they are the domestic leader in three biologics. With 350+ brands, five R&D centers and 13 manufacturing facilities established across the country, we have ensured a strong presence not just in India but also outside India with a wide network across 70+ countries. Our API facilities ensures that our supply chain is vertically integrated providing flexibility over control of manufacturing. We have cemented strategic global partnerships that are a result of alliances with local and multi-national companies which are at the helm of leadership in key therapeutic areas. The key objective of our widespread presence across markets is to constantly innovate and deliver affordable & high-quality healthcare solutions to people.

Polpharma Group serves as a top-tier pharmaceutical manufacturer in Europe and a reliable partner for pharmaceutical firms globally. With a wide range of products (Rx, CHC, APIs), expert services, and competencies across the value chain, along with extensive knowledge of local CEE/CIS markets, it provides distinct growth opportunities for B2B partners. Collaborating with Polpharma Group offers access to a supportive environment, guidance from skilled professionals, and cutting-edge resources. The company actively seeks partners across various areas of operation, from product development and production to commercial cooperation. Additionally, Polpharma API, a Poland-based CDMO specializing in active pharmaceutical ingredients (APIs), stands as a significant European API supplier, catering to pharmaceutical companies worldwide. The company is in the process of a $45 million manufacturing expansion, incorporating HPAPI and cryogenic technologies, with investments in a pilot plant and R&D capabilities. Operations are set to expand from mid-2023, with full completion expected by 2026.

Polepharma has been organizing and advancing the pharmaceutical industry in France, specializing in the biopharmaceutical sector for two decades. It has developed into the leading European hub for drug production, facilitating collaboration between excellence centers and industry stakeholders. Polepharma is committed to three collective principles, including the bold ambition to position France as the global leader in pharmaceutical development. On the other hand, Polpharma is a prominent CDMO and API producer based in Poland. With over 70 years of expertise, it stands as the largest API manufacturer in Poland, offering a comprehensive range of materials from clinical quantities to market supply. The company has fully integrated its operations, covering R&D to manufacturing, to provide cost-effective and timely solutions to its clients. Furthermore, Polpharma has made significant investments to enhance its API plant in Starogard Gdanski, incorporating HPAPI and cryogenic technologies, along with a pilot plant and R&D capabilities.

We are committed to providing innovative and quality medicines to the nearly 200 million people we serve around the world every day; we make contact with patients, families and communities for better health and better days.

Lunan Pharma is a prominent pharmaceutical firm dedicated to enhancing human well-being through the production and promotion of top-quality pharmaceutical products. The company achieved total sales revenues of 1.8 billion dollars in 2020 and is ranked among the top 22 in China.

Nifty Labs Private Limited was established in March 2005. The corporation has specialized in the production of Active Pharmaceutical Ingredients (APIs) and advanced Intermediates for APIs.

COSMA S. P. A. (established in 1977) and AMSA S. P. A. (established in 1953) are a pair of chemical facilities widely recognized globally and particularly valued in the occidental world and in the nations that adhere to the Pharmaceutical Inspection Convention (PIC). They are part of the CFM Group, a privately-owned company engaged in the fields of chemistry and pharmaceuticals since 1949

Chemi S.p.A. is a prominent Italian pharmaceutical company specializing in the research, development, and manufacturing of high-quality generic drugs and active pharmaceutical ingredients (APIs). With over 50 years of experience, Chemi S.p.A. is renowned for its expertise in complex chemistry and its commitment to innovation. The company operates in various therapeutic areas, including oncology, cardiovascular diseases, and central nervous system disorders, providing advanced healthcare solutions to patients globally.

A trusted Indian pharmaceutical company with strong people and technology capabilities, providing affordable, high-quality products that meet the healthcare needs of people across the globe.

Established in 1977 and initially reviewed by the FDA in 1984, COSMA SpA stands as the primary facility within the group, specializing in high-volume APIs with a reaction volume surpassing 130 m3. A modern, cutting-edge expansion of production capabilities was completed in 2011 and 2012.

Located within the boundaries of Tekirdağ, Ulkar Kimya is a joint- stock company of Ulkar Holding and is specialized in the manufacture of drug substance and coated mikropellets. Ulkar Kimya started producing of active drug ingredients in 1988 and subsequently, after building a separate plant, it began to produce mikropellets in 2001. And in 2005, it was decided to expand its production facilities and laboratories in order to be able to meet increasing demands by the clients. Within this context, its new Quality Control Laboratories were put into operation in 2007 and it completed the new drug substance production plant at the end of 2009. As a result of this expansion, an increase of about six-fold was achieved in capacity.

Zhejiang Chiral Medicine Chemicals Co.,Ltd. (CMC) was established in 1998, acquired by Zhejiang Yongtai Technology Co., Ltd. in 2016.Zhejiang Chiral became a wholly-owned subsidiary of Yongtai Technology Co., Ltd. Located in Xiaoshan Nanyang Economic Development Zone, Zhejiang Chiral Medicine Chemicals Co., Ltd occupies an area of 15,000 square meters. The company, specializing in generic APIs and pharmaceutical intermediates, has been accredited as a high-tech enterprise by Zhejiang Province Government.

Through collaboration with distributors and suppliers with established records of excellence, we are constructing a top-notch infrastructure embodying the expertise, attentiveness, and customer care of a local distributor. The ChemSource team is dedicated to offering purchasers the most efficient procurement experience. ChemSource is situated in the Bell Works metroburb, a truly inspiring work environment in Holmdel, New Jersey. Occupying a 2 million square foot building, Bell Works functions as a small city neighborhood, featuring retail stores, restaurants, bars, a coffee shop, and even a hair salon as part of its community, with more amenities on the horizon.